Rhythm begins clinical trials of Setmelanotide for treatment of Prader-Willi syndrome obesity
Biopharmaceutical firm Rhythm has started two Phase II clinical trials to assess the safety and effectiveness of setmelanotide (RM-493) for rare genetic disorders of obesity.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Clinical Trials | Eating Disorders & Weight Management | Genetics | Obesity | Pharmaceuticals | Prader-Willi Syndrome